Citation Impact
Citing Papers
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney
2006 StandoutNobel
Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis
2011
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
2017
Update in podocyte biology
2001
Antihypertensive agents for preventing diabetic kidney disease
2005
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
2008 Standout
Diabetic retinopathy
2010 Standout
Effects of blood pressure lowering on outcome incidence in hypertension
2016
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 Standout
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
2004 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat
2001
ACE Inhibitors to Prevent End-Stage Renal Disease
2001
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
2011
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
2014
Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
2005
Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials
2013
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
2011 Standout
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Evidence for renoprotection by blockade of the renin–angiotensin–aldosterone system in hypertension and diabetes
2006
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
2016 Standout
Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama Study
2010
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
2013
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents
2017 Standout
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses
2016
NF-κB inhibition delays DNA damage–induced senescence and aging in mice
2012
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective
2006
Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients
2006
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
2007
Chronic kidney disease
2011 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Mice with Cardiac-Restricted Angiotensin-Converting Enzyme (ACE) Have Atrial Enlargement, Cardiac Arrhythmia, and Sudden Death
2004 StandoutNobel
Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C
2012 Standout
Diabetic Retinopathy
2012 Standout
Diabetes in Asia
2009 Standout
Role of Remission Clinics in the Longitudinal Treatment of CKD
2008
Kidney-Heart Interactions
2005
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
The Kidney, Hypertension, and Remaining Challenges
2009
US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008
2010 Standout
Cardiorenal Syndrome
2008 Standout
Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system
2005 StandoutNobel
Adiponectin regulates albuminuria and podocyte function in mice
2008
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the Centers for Disease Control and Prevention
2009
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Chronic kidney disease: global dimension and perspectives
2013 Standout
Worldwide access to treatment for end-stage kidney disease: a systematic review
2015 Standout
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
2013
Microalbuminuria and Endothelial Dysfunction: Emerging Targets for Primary Prevention of End-organ Damage
2006
Effect of Intensive Blood Pressure Control With Valsartan on Urinary Albumin Excretion in Normotensive Patients With Type 2 Diabetes
2006
Comparison of RNA isolation and associated methods for extracellular RNA detection by high-throughput quantitative polymerase chain reaction
2016 StandoutNobel
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
2008
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients
2011
Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
2009
Screening, Monitoring, and Treatment of Albuminuria
2006
Effects of Blood Pressure Reduction in Mild Hypertension
2014
The RAAS in the pathogenesis and treatment of diabetic nephropathy
2010
Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials
2016
The Hallmarks of Aging
2013 Standout
Urinary MicroRNA Profiling in the Nephropathy of Type 1 Diabetes
2013
The effect of RAAS blockade on the progression of diabetic nephropathy
2013
Kidney regeneration
2010
A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA
2007
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
2015 Standout
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
2011
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases
2004
Adipose Tissue as an Endocrine Organ
2004 Standout
Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
2010 Standout
Early recognition and prevention of chronic kidney disease
2010
Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy
2004
Mortality Rates in Trials of Subjects With Type 2 Diabetes
2012
Antihypertensive agents for preventing diabetic kidney disease
2012
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
Cell Biology of the Glomerular Podocyte
2003 Standout
Dissecting racial bias in an algorithm used to manage the health of populations
2019 StandoutScience
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
2006
Effect of Telmisartan on Renal Outcomes
2009
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
2013 Standout
Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes
2009
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trial
2017
Community-Based Screening for Chronic Kidney Disease, Hypertension and Diabetes in Dharan
2013
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
2014
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus
2004 Standout
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
2012
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Mechanisms of Diabetic Complications
2013 Standout
Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?
2006
Blood Pressure Lowering in Type 2 Diabetes
2015
Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II–Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?
2009
Harmonizing the Metabolic Syndrome
2009 Standout
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
2011
Progression, remission, regression of chronic renal diseases
2001
Chronic Renal Diseases: Renoprotective Benefits of Renin–Angiotensin System Inhibition
2002
Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga
2014
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
2003 Standout
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of Anna Fassi being referenced
Effect of angiotensin II antagonism on the regression of kidney disease in the rat
2002
Preventing Microalbuminuria in Type 2 Diabetes
2004
ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy
1999
Preventing microalbuminuria in type 2 diabetes
2005
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial
2010